Showing results (591-600 of 667) with videos related to

Sort By:
Pageof 67
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
CA: a Cancer Journal for Clinicians|August 2, 2022
The contemporary management of cancers of the sinonasal tract in adultsRajat Thawani, Myung Sun Kim, Asad Arastu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumourSuzanne George, Ping Chi, Michael C Heinrich, et al.
International Journal of Molecular Sciences|March 8, 2018
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA GeneValentina Indio, Annalisa Astolfi, Giuseppe Tarantino, et al.
Blood|March 16, 2007
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemiaTing-lei Gu, Thomas Mercher, Jeffrey W Tyner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorMichael C Heinrich, Robert G Maki, Christopher L Corless, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II StudyMargaret von Mehren, Suzanne George, Michael C Heinrich, et al.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialRobin L Jones, César Serrano, Margaret von Mehren, et al.
Pageof 67